Chymase is a potent and specific angiotensin II (Ang II)-forming enzyme in vitro. There is also strong evidence to suggest its importance in vivo. Recent clinical studies have suggested that high serum cholesterol levels are associated with increased vascular chymase activity and this may assist in the development of atherosclerosis. This clinical finding has been reproduced in hamster models. Studies with transgenic mice overexpressing the human chymase gene suggest a direct association between vascular chymase upregulation and atherogenesis. There is also increased chymase activity following various cardiac diseases such as myocardial ischaemia, volume overload cardiac failure, cardiomyopathy and viral myocarditis, suggesting that increased cardiac chymase activity appears to be involved in cardiac remodelling.
Introduction
Ang II is the final biological effector of the reninangiotensin-aldosterone system (RAAS). A crucial step in the formation of Ang II is the conversion of the precursor angiotensin I into Ang II. The most common synthesis pathway uses the angiotensinconverting enzyme (ACE), but the importance of alternative pathways has become increasingly apparent in recent years. The most significant among these alternative pathways in vitro is the one involving chymase, and recent data suggests that chymase-dependent Ang II formation is important in vivo as well. 1
Localisation of chymase
Several investigators have reported chymase activity in the heart and coronary arteries. 2, 3, 4 The gene encoding chymase was first cloned in 1991. 5 Since then, the chymase pathway has been shown to be important in the normal adult human myocardium and also other organs: the kidney, muscle cells, mesenchymal cells and endothelial cells. 6 Early studies in patients following myocardial infarction (MI), treated with an ACE inhibitor, showed a correlation between the development of heart failure (HF) and increased Ang II levels in plasma. 7 This suggested that chymase-dependent Ang II formation may be increased in the cardiac remodelling process post-MI.
Clinical studies
This hypothesis was tested in the human autopsy heart. After MI occurs, there is an increase in chymase-dependent Ang II formation in the myocardium ( Figure 1 ). A majority of chymase-containing muscle cells appeared in the epicardium. There is also an increase in epicardial T lymphocytes and macrophages, which can produce ACE. These changes were also evident in the non-infarcted areas of the heart ( Figure 2 ). 8 Similar increases in cardiac Ang II formation were reported in artificial mitral valve regurgitation, which caused volumeoverloaded HF. 9 They showed that both cardiac chymase and ACE activity were increased significantly compared with controls. 
Animal models
The choice of experimental model for the chymase system is not easy because there are considerable differences in chymase activity between species and organs. 10 Among several species, hamster appears to be the most appropriate model, because it possesses human type Ang II-forming chymase. In the cardiomyopathic hamster, chymase mRNA levels and enzymatic activity were elevated before and after HF symptoms developed, 11, 12 indicating activation of the chymase system before the advent of HF. Another hypothesis was that chymase-dependent Ang II formation is upregulated in hypertension. However, results from a hamster hypertension model showed no significant effect on blood pressure (BP) from this pathway of Ang II formation, since an ACE inhibitor and an angiotensin receptor blocker were equally effective in the hamster 2K-1C model. 13 In this same model, however, cardiac and aortic levels of chymase activity and RNA were significantly increased, implicating a potential involvement of chymase pathway in the tissue remodelling process.
The cardiac Ang II-forming system in heart failure
To summarise, studies of the cardiac Ang II-forming system in HF show that hypertensive reactions, ischaemia, cardiomyopathy and myocarditis can stimulate chymase production ( Figure 3 ).The subsequent Ang II formation contributes to the development of cardiac enlargement, hypertrophy and fibrosis involved in the build-up to HF. This may in turn stimulate some of the humoral factors, leading to a vicious cycle of RAAS stimulation with further tissue remodelling. Interfering with this vicious cycle is a prime objective of therapy for HF. ACE inhibitors, though of proven efficacy, are still associated with high morbidity and mortality rates.A more complete blockade of the RAAS may be obtained with highly selective Ang II receptor blockers such as valsartan. In fact, the result of Val-HeFT suggested that additional use of valsartan on top of conventional therapy for patients with heart failure further induced symptomatic and functional improvement.
Chymase and atherosclerosis 14
A recent clinical study showed significantly increased chymase-dependent Ang II formation in atherosclerotic lesions in the human aorta. 15 However, neither the cause nor the result of this were determined. Further studies showed that serum total and LDL-cholesterol levels were significantly correlated to arterial chymase activity in patients undergoing coronary artery bypass operations. 16 These factors suggest that high serum cholesterol levels lead to increased vascular chymase activity and may assist in the development of atherosclerotic lesions. This hypothesis was supported by studies in animal models of atherosclerosis. 17 Syrian hamsters fed with a high cholesterol diet, containing 0.5% cholesterol, display an increase in blood cholesterol levels from 150 mg/dL to 500 mg/dL. In these animals, chymase activity was significantly increased and positively correlated with LDL-cholesterol levels. The animals exhibited significant lipid deposition in the aortic cusp, a deposition which was almost eliminated upon treatment with a non-peptide chymase inhibitor.
Transgenic mouse model 18 To confirm these findings, a transgenic mouse model was developed that overexpresses the human chymase gene. These mice show a typical phenotype of hair loss, reduced body weight, reduction in lipid tissue, and leukocytosis. When fed a high-cholesterol diet, animals exhibit a significantly greater lipid deposition in the aortic cusp region compared with controls. These data indicate a direct association between vascular chymase upregulation and atherogenesis.
Conclusions
In the normal situation, chymase-containing muscle cells are quiescent. Following an increase in plasma cholesterol levels, adventitial chymase-containing muscle cells are stimulated to produce and release chymase, leading to increased local levels of Ang II. In vitro data suggest that chymase contributes directly to atherosclerosis as well as by stimulating the production of Ang II.These direct The cardiac angiotensin II-forming system in heart failure.
Figure 2
Angiotensin II-forming activity in non-AMI and AMI heart. SNS = sympathic nerve system; RAS = renin-angiotensin system; HF = heart failure.
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effects may include degradation of fibronectin and vitronectin, activation of procollagenase and gelatinase B, activation of interleukin-β and production of endothelin (1-31). All these effects may be involved in cardiac remodelling. Thus, improved methods to minimise the chymase-dependent actions of Ang II, such as the use of selective Ang II receptor blockers, are of great importance in attempts to prevent heart conditions from developing into disease states (Figure 4 ). 
Journal of the Renin-Angiotensin-Aldosterone System

